sintilimab   Click here for help

GtoPdb Ligand ID: 12990

Synonyms: IBI 308 | IBI-308 | IBI308 | Tyvyt®
Approved drug Immunopharmacology Ligand
sintilimab is an approved drug (China (2018))
Compound class: Antibody
Comment: Sintilimab (IBI 308) is a fully human IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody [5]. It acts as an immune checkpoint inhibitor and is used clinically as an immuno-oncology therapeutic.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Sintilimab (IBI 308) was granted first approval in China in December 2018, to treat relapsed/refractory classical Hodgkin's lymphoma [2].Elsewhere it is in advanced clinical evaluation as an immunotherapy for solid tumours and haematological malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05171660 Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer Phase 3 Interventional Second Affiliated Hospital, School of Medicine, Zhejiang University 1
NCT04277663 The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery Phase 3 Interventional Innovent Biologics (Suzhou) Co. Ltd.
NCT03150875 A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC Phase 3 Interventional Innovent Biologics (Suzhou) Co. Ltd.
NCT03802240 Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure Phase 3 Interventional Innovent Biologics (Suzhou) Co. Ltd.
NCT03114683 Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma Phase 2 Interventional Innovent Biologics (Suzhou) Co. Ltd. 3
NCT03745170 Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer Phase 3 Interventional Innovent Biologics (Suzhou) Co. Ltd. 4